ImmunoPrecise Antibodies Advances Anti-Aging Research with Mayo Clinic, Leveraging AI Technology

ImmunoPrecise Antibodies Contributes to Groundbreaking Anti-Aging Research

ImmunoPrecise Antibodies Ltd. (IPA), an AI-driven biotherapeutic research and technology company, has made a significant contribution to a groundbreaking study on aging and mitochondrial health. The research, led by top scientists at the Mayo Clinic, was recently published in the prestigious journal Autophagy 1

1

Study Focus and IPA's Role

The study, titled "Development and Characterization of Phospho-Ubiquitin Antibodies to Monitor PINK1-PRKN Signaling in Cells and Tissue," focuses on developing antibodies that detect damaged mitochondria, which become more prevalent as we age. IPA played a crucial role in this project by applying its proprietary rabbit B Cell Select™ platform to isolate and generate highly specific antibodies targeting phosphorylated ubiquitin (p-S65-Ub), a marker of mitochondrial damage 2

2

Implications for Neurodegenerative Diseases

This research advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like Parkinson's and Alzheimer's. The antibodies developed allow researchers to measure mitochondrial health and the progression of damage related to aging, potentially leading to improved diagnostic, prognostic, and therapeutic approaches 1

1

IPA's Technological Contributions

IPA's advanced antibody discovery process was instrumental in the research. Using the B Cell Select™ platform, IPA isolated specific immune cells from immunized rabbits and meticulously screened them to identify those producing antibodies highly specific to phosphorylated ubiquitin. From the top-performing cells, IPA generated and validated recombinant antibodies, ensuring optimal sensitivity and accuracy in detecting damaged mitochondria 2

2

Related Stories

ImmunoPrecise Secures $30 Million Financing Agreement with Yorkville Advisors Global LP

ImmunoPrecise Antibodies Reschedules Financial Results and Business Highlights Report

ImmunoPrecise Antibodies Reschedules Q3 Fiscal 2025 Financial Results Amid AI-Powered Antibody Discovery Progress

Insilico Medicine Unveils AI-Driven Longevity Vaccines to Target Cellular Drivers of Age-Related Diseases

Market Potential and Strategic Positioning

IPA is strategically positioned to capitalize on the booming anti-aging market, projected to reach $81.8 billion by 2028 with an 8.5% CAGR. The company's proprietary B cell Select platform demonstrates its innovative capacity in this high-growth sector. While collaborating with Mayo Clinic on groundbreaking research, IPA simultaneously maintains a robust internal pipeline through its subsidiary, Talem Therapeutics, focusing on next-generation therapeutic antibodies 1

1

Future Outlook and Potential Impact

Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies, emphasized the significance of this research, stating that the novel recombinant p-S65-Ub antibodies represent a significant advancement in mitochondrial research. These proprietary high-precision tools not only enhance our understanding of PINK1-PRKN mediated signaling but also show promising biomarker potential for various clinical applications 2

2